JIC Venture Growth Investments
VC Fund
Marunouchi, Japan
JIC Venture Growth Investments is a VC fund in Marunouchi focused on Information Technology and Medical. JIC-VGI helps promote innovation and improve its international competitiveness through growth-investments in startup companies. The firm accelerating innovation and helping to solve industrial and social issues by supporting and seeking innovative technologies and new businesses. JIC Venture Growth Investments was established in July 2020 and is based in Tokyo, Japan.
- Total investments:
- 113
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $1.1B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries JIC Venture Growth Investments invests in
Stages JIC Venture Growth Investments invests in
Countries JIC Venture Growth Investments invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.1M–$63M
- Series B
- $4.1M–$52M
- Series C
- $4.3M–$77M
Investment Focus
Industry
- Information Technology 14 (12%)
- Medical 13 (12%)
- Software 13 (12%)
- Health Care 13 (12%)
- Biotechnology 11 (10%)
Stage
- Series B 28 (25%)
- Series C 19 (17%)
- Series A 18 (16%)
- Venture - Series Unknown 14 (12%)
- Series D 9 (8%)
Country
- Japan 81 (72%)
- United States 5 (4%)
- Singapore 3 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hideki Yarimizu
CEO, President & Founder
|
CEO, President & Founder | Total investments: 5 | Find email | |
|
Yoshiharu Uruno
Venture capitalist
|
Venture capitalist | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| QibiTech created HATS, a service in which a human operator remotely supplements the operation of a robot. Add-on edge calculator or software for various robots to increase robot flexibility. It also serves as a platform for connecting operation data to the business improvement system. | $3.8M / Series B / Sep 30, 2026 | ||
| SiccaNova Therapeutics is a Japanese biopharmaceutical company dedicated to treating sicca (dryness) related medical conditions. The company’s lead drug candidate, XF8302, is a novel, small-molecule M3 muscarine receptor Positive Allosteric Modulator (M3 PAM). Developed initially for dry mouth in Sjögren’s syndrome patients, the drug enhancesnatural acetylcholine signaling to stimulate salivation without the systemic side effects common in traditional agonists. | $7.9M / Series A / Sep 03, 2026 | ||
| Paytner is providing services to support freelance people's funding. The freelance population in Japan has been shown to continue to increase in many Chosa. While working styles are diversified, they are not able to respond to the development of the working environment, and they will develop their business to change the situation whereproblems such as funding, credit, sexual harassment, and power harassment are accumulated. | $14.4M / Series D / Sep 01, 2026 | ||
| elleThermo aims to implement Semiconductor-Sensitised Thermal Cells (STCs), an energy conversion technology that can generate electricity from unused waste heat above room temperature. | $5.2M / Series A / Aug 26, 2026 | ||
| HERP is a recruitment management platform. | $11.9M / Series C / Aug 25, 2026 | ||
| Kyoto Fusioneering is a research & development, design, and manufacture of parts related to fusion reactors. | $105.3M / Series D / Aug 24, 2026 | ||
| Letara operates a space technology platform with the intention to serve a logistics network covering the solar system. The company produces hybrid propulsion engines for small spacecraft, promoting groundbreaking advances in space propulsion with high thrust, safe, and inexpensive propulsion system technology. | $16.4M / Seed / Aug 20, 2026 | ||
| BiPSEE is a medical XR company that provides treatment support for children for the purpose of nurturing a sense of self-efficacy. They also deploy AR and VR animation with one button dentistry and medicine, whether outpatient or hospitalized in various situations your child's anxiety and pain relieve. It aims to reduce anxiety and pain inchildren in a wide range of medical fields such as dentistry, pediatrics, and dermatology.BiPSEE is abs ed in Tokyo, Japan. | Series A / Aug 17, 2026 | ||
| RoboTruck develops autonomous driving technologies for huge trucks, as well as practical applications. | $31.8M / Series A / Jul 30, 2026 | ||
| Bitkey is a company provides its own key technology. | $24.6M / Venture - Series Unknown / Jul 01, 2026 | ||
| See all 113 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does JIC Venture Growth Investments invest in?
JIC Venture Growth Investments invests primarily in Information Technology, Medical and Software startups, most often at Series B and Series C stage. Most of the 113 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does JIC Venture Growth Investments invest in?
JIC Venture Growth Investments typically joins rounds of $3.1M–$63M at Series A, $4.1M–$52M at Series B and $4.3M–$77M at Series C. These are whole funding-round sizes, not JIC Venture Growth Investments's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds JIC Venture Growth Investments took part in.
How do I contact JIC Venture Growth Investments?
Public channels for JIC Venture Growth Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at JIC Venture Growth Investments?
The team at JIC Venture Growth Investments includes Hideki Yarimizu (CEO, President & Founder) and Yoshiharu Uruno (Venture capitalist). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
